Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity

Basit Öğe Kaydı
dc.contributor.authorSahin, A.
dc.contributor.authorGursel-Ozkurt, Z.
dc.contributor.authorSahin, M.
dc.contributor.authorTurkcu, F. M.
dc.contributor.authorYildirim, A.
dc.contributor.authorYuksel, H.
dc.date.accessioned2024-04-24T16:02:34Z
dc.date.available2024-04-24T16:02:34Z
dc.date.issued2018
dc.departmentDicle Üniversitesien_US
dc.description.abstractWe aimed to investigate the effectivity of the 0.0625 mg dose of bevacizumab in patients with retinopathy of prematurity (ROP) and compare the results with 0.625 mg dose of intravitreal bevacizumab (IVB) injection. The medical records of the patients with type 1 ROP who received IVB monotherapy were retrospectively reviewed. Demographic and clinical characteristics of the patients were recorded. The patients were classified into two groups with respect to received dose of bevacizumab as follows: group F (n = 46) (full dose of bevacizumab-0.625 mg/0.025 ml) and group L (n = 45) (low dose (one tenth) of bevacizumab-0.0625 mg/0.025 ml). Both treatment dose regimens have similar outcomes. Moreover, the mean retinal vascularization time seemed to be significantly higher in group F compared to group L, 168 +/- 65 and 97 +/- 29 days, respectively (p < 0.001). Disappearance of plus sign is observed earlier in group F (2.45 +/- 1.7 vs 3.66 +/- 2.46 days, respectively, p = 0.03). The low dose (0.0625 mg) of IVB treatment was effective as full (0.625 mg) dose in ROP treatment. Moreover, our results showed that low-dose treatment might provide faster retinal vascularization than the regular used dose. On the other hand, disappearance of the plus sign takes longer time in patients treated with low dose compared to eyes treated with full dose of IVB that should be taken into account.en_US
dc.identifier.doi10.1007/s11845-017-1684-y
dc.identifier.endpage421en_US
dc.identifier.issn0021-1265
dc.identifier.issn1863-4362
dc.identifier.issue2en_US
dc.identifier.pmid28988372
dc.identifier.scopus2-s2.0-85030667418
dc.identifier.scopusqualityQ1
dc.identifier.startpage417en_US
dc.identifier.urihttps://doi.org/10.1007/s11845-017-1684-y
dc.identifier.urihttps://hdl.handle.net/11468/14842
dc.identifier.volume187en_US
dc.identifier.wosWOS:000431325400024
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofIrish Journal of Medical Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIntravitreal Bevacizumaben_US
dc.subjectLow Doseen_US
dc.subjectRetinal Vascularizationen_US
dc.subjectRetinopathy Of Prematurityen_US
dc.titleUltra-low dose of intravitreal bevacizumab in retinopathy of prematurityen_US
dc.titleUltra-low dose of intravitreal bevacizumab in retinopathy of prematurity
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu